Qbrexza is an officially Food and Drug Administration-approved prescription medication formulated as a topical 2.4 percent glycopyrronium cloth designed for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating, in adult and pediatric patients aged nine years and older. Clinical trials reviewed by regulatory bodies demonstrated its efficacy in reducing sweat production, leading to its clearance as a convenient once-daily topical anticholinergic wipe intended exclusively for underarm application under medical supervision.